Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001214659-25-016716·ArriVent BioPharma, Inc.
Schedule 13G ownership disclosure
ArriVent Biopharma Inc
Common Stock, $0.0001 par value · CUSIP: 04272N102
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Octagon Capital Advisors LP
Shares: 1,971,054.00 · Class: 4.9%
- Octagon Investments Master Fund LP
Shares: 776,667.00 · Class: 1.9%
- Octagon Private Opportunities Fund LP
Shares: 799,911.00 · Class: 2.0%
- Octagon Special Opportunities Fund LP - Series 4
Shares: 394,476.00 · Class: 1.0%
- Ting Jia
Shares: 1,971,054.00 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-016716
- Form type
- SCHEDULE 13G/A
- Filer
- ArriVent BioPharma, Inc.
- CIK
- CIK 1868279
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership